CYPHERPUNK TECHNOLOGIES INC. (CYPH) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
20/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseCYPH / S&P -23.02% / 15.20% |
LoseCYPH / S&P CYPH unavailable / 15.00% |
LoseCYPH / S&P -135.44% / 50.40% |
| 2026-Q10/3 |
LoseCYPH / S&P -31.47% / -4.33% |
LoseCYPH / S&P CYPH unavailable / 11.30% |
LoseCYPH / S&P -98.82% / 27.70% |
| 2025-Q41/3 |
WinCYPH / S&P 155.51% / 2.65% |
LoseCYPH / S&P CYPH unavailable / 9.00% |
LoseCYPH / S&P -103.80% / 13.40% |
| 2025-Q31/3 |
WinCYPH / S&P 52.86% / 8.12% |
LoseCYPH / S&P CYPH unavailable / 4.61% |
LoseCYPH / S&P -26.95% / 13.45% |
| 2025-Q20/3 |
LoseCYPH / S&P -2.62% / 10.94% |
LoseCYPH / S&P CYPH unavailable / 4.83% |
LoseCYPH / S&P -9.20% / 10.63% |
| 2025-Q10/3 |
LoseCYPH / S&P -89.39% / -4.27% |
LoseCYPH / S&P CYPH unavailable / 4.98% |
LoseCYPH / S&P -20.19% / 10.57% |
| 2024-Q41/3 |
WinCYPH / S&P 11.87% / 2.41% |
LoseCYPH / S&P CYPH unavailable / 5.25% |
LoseCYPH / S&P -62.14% / 6.15% |
| 2024-Q31/3 |
WinCYPH / S&P 31.12% / 5.89% |
LoseCYPH / S&P CYPH unavailable / 5.89% |
LoseCYPH / S&P -70.86% / 6.11% |
| 2024-Q20/3 |
LoseCYPH / S&P -26.32% / 4.28% |
LoseCYPH / S&P CYPH unavailable / 5.38% |
LoseCYPH / S&P -73.44% / 5.12% |
| 2024-Q10/3 |
LoseCYPH / S&P -35.83% / 10.56% |
LoseCYPH / S&P CYPH unavailable / 5.71% |
LoseCYPH / S&P -70.17% / 5.59% |
| 2023-Q42/3 |
WinCYPH / S&P 200.36% / 11.69% |
LoseCYPH / S&P CYPH unavailable / 6.81% |
WinCYPH / S&P 21.80% / 7.78% |
| 2023-Q31/3 |
LoseCYPH / S&P -55.91% / -3.27% |
LoseCYPH / S&P CYPH unavailable / 7.52% |
WinCYPH / S&P 91.00% / -5.03% |
| 2023-Q21/3 |
LoseCYPH / S&P -7.94% / 8.74% |
LoseCYPH / S&P CYPH unavailable / 9.50% |
WinCYPH / S&P 261.88% / -8.57% |
| 2023-Q11/3 |
LoseCYPH / S&P -24.44% / 7.50% |
LoseCYPH / S&P CYPH unavailable / 10.77% |
WinCYPH / S&P 1560.47% / -15.69% |
| 2022-Q41/3 |
LoseCYPH / S&P -48.86% / 7.56% |
LoseCYPH / S&P CYPH unavailable / 11.88% |
WinCYPH / S&P 767.39% / -17.99% |
| 2022-Q31/3 |
LoseCYPH / S&P -23.48% / -4.88% |
LoseCYPH / S&P CYPH unavailable / 13.47% |
WinCYPH / S&P 597.67% / -1.41% |
| 2022-Q21/3 |
LoseCYPH / S&P -34.29% / -16.10% |
LoseCYPH / S&P CYPH unavailable / 13.71% |
WinCYPH / S&P 376.32% / 11.04% |
| 2022-Q10/3 |
LoseCYPH / S&P -45.99% / -4.60% |
LoseCYPH / S&P CYPH unavailable / 15.97% |
LoseCYPH / S&P 13.16% / 42.23% |
| 2021-Q40/3 |
LoseCYPH / S&P -19.20% / 11.03% |
LoseCYPH / S&P 0.00% / 15.00% |
LoseCYPH / S&P -43.21% / 96.40% |
| 2021-Q31/3 |
WinCYPH / S&P 144.51% / 0.58% |
LoseCYPH / S&P CYPH unavailable / 10.77% |
LoseCYPH / S&P -60.19% / 69.42% |
| 2021-Q20/3 |
LoseCYPH / S&P -13.68% / 8.55% |
LoseCYPH / S&P CYPH unavailable / 6.58% |
LoseCYPH / S&P -71.21% / 51.81% |
| 2021-Q10/3 |
LoseCYPH / S&P -15.56% / 6.17% |
LoseCYPH / S&P CYPH unavailable / -1.06% |
LoseCYPH / S&P -75.80% / 7.39% |
| 2020-Q41/3 |
WinCYPH / S&P 13.64% / 12.15% |
LoseCYPH / S&P CYPH unavailable / -3.72% |
LoseCYPH / S&P -45.64% / -33.42% |
| 2020-Q30/3 |
LoseCYPH / S&P -5.26% / 8.93% |
LoseCYPH / S&P CYPH unavailable / -2.04% |
LoseCYPH / S&P -28.95% / -27.10% |
| 2020-Q22/3 |
WinCYPH / S&P 32.28% / 20.54% |
LoseCYPH / S&P CYPH unavailable / -0.46% |
WinCYPH / S&P -24.14% / -27.11% |
| 2020-Q11/3 |
WinCYPH / S&P 41.07% / -19.60% |
LoseCYPH / S&P CYPH unavailable / 3.47% |
LoseCYPH / S&P CYPH unavailable / -14.75% |
| 2019-Q40/3 |
LoseCYPH / S&P -4.27% / 9.07% |
LoseCYPH / S&P CYPH unavailable / 5.36% |
LoseCYPH / S&P CYPH unavailable / 2.99% |
| 2019-Q30/3 |
LoseCYPH / S&P -34.64% / 1.70% |
LoseCYPH / S&P CYPH unavailable / 5.02% |
LoseCYPH / S&P CYPH unavailable / 0.21% |
| 2019-Q20/3 |
LoseCYPH / S&P -4.28% / 4.30% |
LoseCYPH / S&P CYPH unavailable / 6.64% |
LoseCYPH / S&P CYPH unavailable / 8.65% |
| 2019-Q10/3 |
LoseCYPH / S&P -6.50% / 13.65% |
LoseCYPH / S&P CYPH unavailable / 8.12% |
LoseCYPH / S&P CYPH unavailable / 14.29% |
| 2018-Q40/3 |
LoseCYPH / S&P -74.33% / -13.52% |
LoseCYPH / S&P CYPH unavailable / 9.05% |
LoseCYPH / S&P CYPH unavailable / 18.23% |
| 2018-Q30/3 |
LoseCYPH / S&P -13.44% / 7.71% |
LoseCYPH / S&P CYPH unavailable / 10.21% |
LoseCYPH / S&P CYPH unavailable / 19.06% |
| 2018-Q21/3 |
WinCYPH / S&P 8.43% / 3.43% |
LoseCYPH / S&P CYPH unavailable / 9.03% |
LoseCYPH / S&P CYPH unavailable / 14.46% |
| 2018-Q11/3 |
WinCYPH / S&P 33.01% / -0.76% |
LoseCYPH / S&P CYPH unavailable / 7.68% |
LoseCYPH / S&P CYPH unavailable / 12.46% |
| 2017-Q41/3 |
WinCYPH / S&P 9.28% / 6.64% |
LoseCYPH / S&P CYPH unavailable / 7.03% |
LoseCYPH / S&P CYPH unavailable / 13.82% |
| 2017-Q30/3 |
LoseCYPH / S&P -13.22% / 4.48% |
LoseCYPH / S&P CYPH unavailable / 5.68% |
LoseCYPH / S&P CYPH unavailable / 17.57% |
| 2017-Q20/3 |
LoseCYPH / S&P -28.32% / 3.09% |
LoseCYPH / S&P CYPH unavailable / 4.83% |
LoseCYPH / S&P CYPH unavailable / 17.74% |
| 2017-Q10/3 |
LoseCYPH / S&P CYPH unavailable / 6.07% |
LoseCYPH / S&P CYPH unavailable / 3.67% |
LoseCYPH / S&P CYPH unavailable / 13.32% |
| 2016-Q40/3 |
LoseCYPH / S&P CYPH unavailable / 3.82% |
LoseCYPH / S&P CYPH unavailable / 2.09% |
LoseCYPH / S&P CYPH unavailable / 7.05% |
| 2016-Q30/3 |
LoseCYPH / S&P CYPH unavailable / 3.85% |
LoseCYPH / S&P CYPH unavailable / 0.20% |
LoseCYPH / S&P CYPH unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CYPH total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 556.25% | 20.78% |
| Annualized return | 556.25% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | CYPH total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -89.01% | 83.14% |
| Annualized return | -35.70% | 12.86% |
10Y · 2017-01-25 to 2026-08-27
| Metric | CYPH total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -97.60% | 319.30% |
| Annualized return | -31.12% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |